These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 37865690)

  • 1. Computational prognostic evaluation of Alzheimer's drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches.
    Hassan M; Shahzadi S; Yasir M; Chun W; Kloczkowski A
    Sci Rep; 2023 Oct; 13(1):18022. PubMed ID: 37865690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches.
    Hassan M; Raza H; Abbasi MA; Moustafa AA; Seo SY
    Biomed Pharmacother; 2019 Jan; 109():2513-2526. PubMed ID: 30551512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies.
    Hassan M; Yasir M; Shahzadi S; Kloczkowski A
    ACS Omega; 2022 Jun; 7(23):19243-19260. PubMed ID: 35721972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease.
    Shukla R; Singh TR
    J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational investigation of mechanistic insights of Aβ42 interactions against extracellular domain of nAChRα7 in Alzheimer's disease.
    Hassan M; Shahzadi S; Raza H; Abbasi MA; Alashwal H; Zaki N; Moustafa AA; Seo SY
    Int J Neurosci; 2019 Jul; 129(7):666-680. PubMed ID: 30422726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic identification and repurposing of FDA-approved drugs as antibacterial agents against Streptococcus pyogenes: In silico and in vitro studies.
    Gracia J; Perumal D; Dhandapani P; Ragunathan P
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128667. PubMed ID: 38101681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing of phyto-ligand molecules from the honey bee products for Alzheimer's disease as novel inhibitors of BACE-1: small molecule bioinformatics strategies as amyloid-based therapy.
    Nisa N; Rasmita B; Arati C; Uditraj C; Siddhartha R; Dinata R; Bhanushree B; Bidanchi RM; Manikandan B; Laskar SA; Abinash G; Pori B; Roy VK; Gurusubramanian G
    Environ Sci Pollut Res Int; 2023 Apr; 30(17):51143-51169. PubMed ID: 36808033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-based drug repurposing against Candida albicans-A computational modeling, docking, and molecular dynamic simulations study.
    Verma R; Pradhan D; Nayek A; Singh H; Jain AK; Khan LA
    J Cell Biochem; 2022 Feb; 123(2):289-305. PubMed ID: 34672012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
    Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
    Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep-learning based repurposing of FDA-approved drugs against
    Joshi T; Pundir H; Chandra S
    J Biomol Struct Dyn; 2022 Nov; 40(18):8420-8436. PubMed ID: 33879017
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
    Kumar R; Jade D; Gupta D
    J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.
    Singh AK; Kushwaha PP; Prajapati KS; Shuaib M; Gupta S; Kumar S
    Comput Biol Med; 2021 Mar; 130():104185. PubMed ID: 33352458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperative hydrogen bonds and mobility of the non-aromatic ring as selectivity determinants for human acetylcholinesterase to similar anti-Alzheimer's galantaminics: a computational study.
    Rocha REO; Lima LHF
    J Biomol Struct Dyn; 2019 Apr; 37(7):1843-1856. PubMed ID: 29697300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation.
    Elangovan ND; Dhanabalan AK; Gunasekaran K; Kandimalla R; Sankarganesh D
    J Biomol Struct Dyn; 2021 Nov; 39(18):7065-7079. PubMed ID: 32779973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease.
    Hassan M; Shahzadi S; Seo SY; Alashwal H; Zaki N; Moustafa AA
    Front Comput Neurosci; 2018; 12():34. PubMed ID: 29910719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Drug Repurposing Approach: Investigation of
    Ngidi NTP; Machaba KE; Mhlongo NN
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163931
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug repurposing for Alzheimer's disease:
    Kumar N; Gahlawat A; Kumar RN; Singh YP; Modi G; Garg P
    J Biomol Struct Dyn; 2022 Apr; 40(7):2878-2892. PubMed ID: 33170091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.